Neuropace, Inc. Common Stock (NPCE)
NeuroPace, Inc. (NPCE) is a medical device company specializing in the development and commercialization of responsive neurostimulation systems for the treatment of neurological disorders, primarily epilepsy. Their flagship product, the RNS System, is designed to detect and respond to abnormal brain activity in real-time, aiming to reduce seizure frequency and improve patient quality of life. Founded in 1997, NeuroPace focuses on innovations in neuromodulation technology to address unmet needs in neurological healthcare.
Company News
NeuroPace, Inc. (NPCE) announced that its NAUTILUS study did not reach statistical significance for the primary effectiveness endpoint, causing its stock price to fall 28.39%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers.
Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts' ratings for NeuroPace (NASDAQ:NPCE) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for NeuroPace, presenting an average target of $16.33, a high estimate of $22.00, and a low estimate of $12.00. Observing a 48.45% increase, the current average has risen from the previous average price target of $11.00. Analyzing Analyst Ratings: A Detailed Breakdown The standing of NeuroPace among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robbie Marcus JP Morgan Raises Overweight $17.00 $9.00 Ross Osborn Cantor Fitzgerald Raises Overweight $18.00 $16.00 Drew Ranieri Morgan Stanley Raises Equal-Weight $13.00 $9.00 Lawrence Biegelsen Wells Fargo Raises Equal-Weight $16.00 $9.00 Mike Kratky Leerink Partners Announces Outperform $22.00 - Frank Takkinen Lake Street Maintains Buy $12.00 $12.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com
NPCE earnings call for the period ending June 30, 2022.